CN107028930A - A kind of antiprostate cancer composition and application thereof - Google Patents
A kind of antiprostate cancer composition and application thereof Download PDFInfo
- Publication number
- CN107028930A CN107028930A CN201710298783.XA CN201710298783A CN107028930A CN 107028930 A CN107028930 A CN 107028930A CN 201710298783 A CN201710298783 A CN 201710298783A CN 107028930 A CN107028930 A CN 107028930A
- Authority
- CN
- China
- Prior art keywords
- prostate cancer
- pharmaceutical composition
- inonotus obliquus
- edible fungus
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of medical composition and its use for anti-prostate cancer, described pharmaceutical composition includes inonotus obliquus and optional edible fungus polysaccharide, and the edible fungus polysaccharide is selected from：One or more in lentinan, pachymaran, GL-B or flammulina velutipes.Pharmaceutical composition of the present invention can effectively suppress propagation and the migration of prostate gland cancer cell, the immunity of patient itself can not only be strengthened after addition edible fungus polysaccharide, the side effect that patients with prostate cancer chemotherapy is brought is reduced, the activity of inonotus obliquus anti-prostate cancer can also be further enhanced, the effect of collaboration anti-prostate cancer is shown.
Description
Technical field
The invention belongs to drug field, in particular it relates to a kind of medical composition and its use of anti-prostate cancer.
Background technology
Prostate cancer is the epithelial malignancy for betiding prostate, multiple to be born in more than 45 years old the elderly, is complete
The second largest male malignancy of ball, in recent years the incidence of disease of China's prostate cancer steeply rise, it is strong as China's middle-aging male
The significant threat of health.
Inonotus obliquus, also known as Polyporus picipes, CHAGA, are a kind of domestomycetes for being grown in frigid zone, are mainly distributed in China
In the big Xiaoxinanlin Mountains and Changbaishan area, the tradition among the people for generally thering is edible Inonotus obliquus to prevent and treat a variety of diseases.Modern study table
Bright Inonotus obliquus includes tens kinds of chemical compositions, mainly including steroid compound, aromatic compound, aliphatic compound
Thing, triterpene compound, lignan derivatives, alkaloid etc..Modern pharmacology research shows that Inonotus obliquus has a variety of pharmacology
Activity, is specifically included：(1) antitumor activity, existing document report Inonotus obliquus has anti-liver cancer and anti-, stomach cancer, lung cancer, cervical carcinoma
Activity；(2) antiviral activity, the alcohol composite extract for having document report Inonotus obliquus has anti HIV-1 virus, the work of influenza virus
Property；(3) diabetes are treated, the water extract of Inonotus obliquus has hypoglycemic activity；(4) hypotensive, Adjust-blood lipid；(5) enhancing is exempted from
Epidemic disease power；(6) it is anti-oxidant；(7) it is anti-ageing to wait for a long time.
The present invention is further screened to its anti-tumor active ingredient, therefrom sieved on the Research foundation of existing Inonotus obliquus
Choosing obtained it is a kind of there is the monomeric compound of excellent inhibition to prostate cancer, and pass through its compounding with other compounds
Research, thus obtain it is a kind of can effective anti-prostate cancer pharmaceutical composition.
The content of the invention
It is an object of the present invention to provide a kind of pharmaceutical composition of anti-prostate cancer, described pharmaceutical composition includes birch
Obliquus and pharmaceutically acceptable carrier.
It is preferred that described pharmaceutical composition using inonotus obliquus as sole active agent.
Further, described pharmaceutical composition also includes edible fungus polysaccharide, it is preferred that the edible fungus polysaccharide choosing
From：Lentinan (being purchased from Xi'an Bai Chuan biotechnologies Co., Ltd), pachymaran (have purchased from Xi'an Bai Chuan biotechnologies
Limit responsible company), GL-B (be purchased from Xi'an Bai Chuan biotechnologies Co., Ltd) or flammulina velutipes (be purchased from Fu Jianhui
Damp bio tech ltd) in one or more.
The weight ratio of inonotus obliquus and edible fungus polysaccharide is in pharmaceutical composition of the present invention：1-3：5-10,
Preferably：1-2:6-8, more have choosing for 1:8.
The pharmaceutical composition of anti-prostate cancer of the present invention can be prepared into combination of oral medication according to this area conventional method,
The combination of oral medication is selected from capsule, tablet or granule, wherein the pharmaceutically acceptable carrier is selected from：Filling
One or more in agent, adhesive, disintegrant or lubricant, it is preferred that the filler be selected from starch, dextrin, lactose or
Microcrystalline cellulose, described adhesive is selected from：Cellulose derivative, pregelatinized starch, PVP, the disintegrant are selected from：Carboxylic first
Base sodium starch, Ac-Di-Sol, PVPP, the lubricant are selected from：Talcum powder, magnesium stearate or micro mist silicon
Glue, it is preferred that the cellulose derivative is selected from：Methylcellulose, hydroxypropyl cellulose, sodium carboxymethylcellulose or ethyl are fine
Dimension element.
It is a further object to provide purposes of the inonotus obliquus in antiprostate cancer is prepared.
Anti- prostatitis is being prepared it is also another object of the present invention to provide the composition of inonotus obliquus and edible fungus polysaccharide
Purposes in gland cancer medicine, it is preferred that the edible fungus polysaccharide is selected from：Lentinan, pachymaran, GL-B or acupuncture needle
One or more in mushroom polysaccharide.
Beneficial effect
Present invention screening in the complicated composition of Inonotus obliquus is obtained substantially suppressing prostate gland cancer cell propagation and migrated
Monomeric compound inonotus obliquus, so as to obtain a kind of pharmaceutical composition with clear and definite anti-prostate cancer effect, pass through
Show with the composition research of other compounds, after inonotus obliquus with edible fungus polysaccharide by compounding, can not only play food
Strengthen immunity of organisms with fungi polysaccharide, reduce the intrinsic effect for the side effect that chemotherapy is brought, birch can also be significantly increased brown
The anti-prostate cancer activity of pore fungi element, shows obvious synergistic function, so as to further provide before a kind of resist
The more excellent pharmaceutical composition of row gland cancer effect.
Embodiment
The present invention is described below in more detail to contribute to the understanding of the present invention.
It should be appreciated that the term or word that use in the specification and in the claims are not construed as having
The implication limited in dictionary, and be interpreted as on the basis of following principle having and its implication one in the context of the present invention
The implication of cause：The concept of term can be limited suitably by inventor for the best illustration to the present invention.
Embodiment 1：A kind of tablet of anti-prostate cancer
The tablet of the anti-prostate cancer is prepared according to following steps：
(1) weigh and crushed respectively after each composition by recipe quantity, cross 80 mesh sieves；
(2) inonotus obliquus of recipe quantity, lentinan, GL-B, microcrystalline cellulose, pregelatinized starch are put into height
Fast wet granulator, adds suitable quantity of water granulation, crosses 20 mesh sieve whole grains after drying, adds the PVPP and stearic acid of recipe quantity
Magnesium, well mixed rear tabletting produces the tablet of anti-prostate cancer of the present invention.
Embodiment 2：A kind of capsule of anti-prostate cancer
The anti-prostate cancer capsule, is prepared in accordance with the following steps：
(1) weigh and crushed respectively after each composition by recipe quantity, cross 100 mesh sieves；
(2) inonotus obliquus of recipe quantity, lentinan, GL-B, microcrystalline cellulose, pregelatinized starch are put into height
Fast wet granulator, adds suitable quantity of water granulation, and 20 mesh sieve whole grains are crossed after drying；
(3) step (2) particle in addition recipe quantity magnesium stearate after be well mixed；
(4) anti-prostate cancer capsule of the present invention is produced in gelatine capsule shell by particles filled obtained by step (3).
Effect example 1：The influence bred to prostate gland cancer cell
1.1 Experimental agents
(1) blank group：The culture medium of serum-free 1640；
(2) inonotus obliquus group：The addition culture medium of serum-free 1640 is configured to the suspension that content is 5%；
(3) polysaccharide group：According to GL-B, lentinan according to 1：1 proportional arrangement is trained into 20% serum-free 1640
Support based sols；
(4) Inonotus obliquus extract group：Inonotus obliquus extract is weighed, the culture medium of serum-free 1640 for being configured to 5% is mixed
Suspension；
(5) complex group：Weigh inonotus obliquus, GL-B and lentinan, be configured to containing 2% inonotus obliquus,
The culture medium of serum-free 1640 of 20% polysaccharide is combined suspension.
1.2 experimental method
Take the logarithm the Human Prostate Cancer Cells (PC-3) in growth period, with 5 × 103The density in/hole is inoculated in 96 orifice plates, per hole
200 μ L, addition is put into 37 DEG C and contains 5%CO after 1640 culture mediums containing 10% hyclone2Incubator in cultivate 24 hours.
96 orifice plates set up blank group, inonotus obliquus group, polysaccharide group, Inonotus obliquus extract group, complex group, every group 10 separately
Multiple holes, each group addition relative medicine, wherein the blank group addition culture medium of serum-free 1640, inonotus obliquus group final concentration of 1%,
Inonotus obliquus is final concentration of in polysaccharide group final concentration of 10%, Inonotus obliquus extract group final concentration of 2%, complex group
0.5%, final concentration of the 5% of polysaccharide, continue to cultivate after 48h, continue to cultivate after 4h, supernatant discarding after addition MTT solution, per hole
Add after DMSO 150 μ L, fully shaking 10min, 570nm absorbances are determined using ELIASA, calculate each group inhibiting rate, tool
Body result is referring to table 1.
Inhibiting rate (%)=(control group-sample sets) control group × 100%
The experimental result of table 1 shows complex polysaccharide, inonotus obliquus and the brown hole of birch that GL-B is constituted with lentinan
Fungus extract shows the activity of certain suppression prostate cancer cell proliferation, and wherein inonotus obliquus suppresses human prostate
Cancer cell multiplication activity highest, hence it is evident that higher than Inonotus obliquus extract group, show that inonotus obliquus has before excellent suppression people
Although the activity of row adenocarcinoma cell propagation, polysaccharide group also show the proliferation activity of certain suppression Human Prostate Cancer Cells, but
Although inonotus obliquus is reduced with inonotus obliquus consumption after polysaccharide group compounding, propagation of the complex group to Human Prostate Cancer Cells
Inhibitory activity is but significantly improved, so as to show that inonotus obliquus has the activity for cooperateing with anti-prostate cancer with edible fungus polysaccharide.
Table 1, the influence bred to PC-3 cells
Effect example 2：Influence to migration of prostate cancer cells.
2.1 Experimental agents
(1) blank group：The culture medium of serum-free 1640；
(2) inonotus obliquus group：The addition culture medium of serum-free 1640 is configured to the suspension that content is 5%；
(3) polysaccharide group：According to GL-B, lentinan according to 1：1 proportional arrangement is trained into 20% serum-free 1640
Support based sols；
(4) Inonotus obliquus extract group：Inonotus obliquus extract is weighed, the culture medium of serum-free 1640 for being configured to 5% is mixed
Suspension；
(5) complex group：Weigh inonotus obliquus, GL-B and lentinan, be configured to containing 2% inonotus obliquus,
The culture medium of serum-free 1640 of 20% polysaccharide is combined suspension.
2.2 experimental method
Take the logarithm the Human Prostate Cancer Cells (PC-3) in growth period, add 24 orifice plates, contain 5%CO in 37 DEG C2Incubator
Middle culture, 1640 culture mediums of the addition containing 10% hyclone, when cell fusion 80%-90%, is replaced by free serum culture
Base, continues to cultivate 12 hours, with 100 μ L liquid transfer gun heads along each bore dia cut of 24 orifice plates, washes cell twice using PBS, discard
After PBS, add after 1640 culture mediums of the equivalent containing 10% hyclone, cut area relative distance D1 is recorded under mirror.24 orifice plates point
If blank group, inonotus obliquus group, polysaccharide group, Inonotus obliquus extract group, complex group, every group of 4 multiple holes, each group addition is corresponding
Medicine, wherein blank group add pure water, inonotus obliquus group final concentration of 1%, polysaccharide group final concentration of 10%, Inonotus obliquus
Inonotus obliquus final concentration of 0.5% in extract group final concentration of 2%, complex group, final concentration of the 5% of polysaccharide, continue to train
Support after 48h, cut area relative distance D2 is measured under mirror, calculate displacement D3 of the cell to region of causing injury.Calculate each group migration
Inhibiting rate, concrete outcome is referring to table 2.
Inhibition of metastasis rate (%)=(control group-sample sets) control group × 100%
Table 2, the influence to PC-3 cell migrations
Note：Compared with blank group：*P<0.05,**P<0.01.
The experimental result of table 2 shows that single inonotus obliquus has the effect for suppressing Human Prostate Cancer Cells migration,
Although Inonotus obliquus extract group also show the effect of certain suppression Human Prostate Cancer Cells migration, but inhibition is not
Substantially, and complex polysaccharide that GL-B and lentinan are constituted does not show the effect for suppressing migration of prostate cancer cells then,
Its final cell migration distance is even also longer than blank group.By inonotus obliquus and GL-B and being combined that lentinan is constituted
Group, the effect for suppressing Human Prostate Cancer Cells migration is the most excellent, hence it is evident that higher than single inonotus obliquus group, so that show,
Can be bright after being compounded without the GL-B, lentinan and inonotus obliquus group that suppress Human Prostate Cancer Cells migration effect
The Human Prostate Cancer Cells inhibition of metastasis effect of aobvious enhancing inonotus obliquus.
Claims (10)
1. a kind of pharmaceutical composition for anti-prostate cancer, it is characterised in that including inonotus obliquus and pharmaceutically acceptable
Carrier.
2. the pharmaceutical composition of anti-prostate cancer according to claim 1, it is characterised in that described pharmaceutical composition is with birch
Obliquus is sole active agent.
3. the pharmaceutical composition of anti-prostate cancer according to claim 1, it is characterised in that described pharmaceutical composition is also wrapped
Include edible fungus polysaccharide.
4. the pharmaceutical composition of anti-prostate cancer according to claim 3, it is characterised in that the edible fungus polysaccharide choosing
From：One or more in lentinan, pachymaran, GL-B or flammulina velutipes.
5. the pharmaceutical composition of anti-prostate cancer according to claim 4, it is characterised in that the inonotus obliquus and food
It is with the weight ratio of fungi polysaccharide：1-3：5-10, preferably：1-2:6-8, more have choosing for 1:8.
6. the pharmaceutical composition of the anti-prostate cancer according to claim 1, any one of 3-5, it is characterised in that the medicine
Composition is combination of oral medication.
7. the pharmaceutical composition of anti-prostate cancer according to claim 6, it is characterised in that the combination of oral medication
Selected from capsule, tablet or granule.
8. the pharmaceutical composition of the anti-prostate cancer according to claim any one of 1-7, it is characterised in that it is described pharmaceutically
Acceptable carrier is selected from：One or more in filler, adhesive, disintegrant or lubricant, it is preferred that the filler
Selected from starch, dextrin, lactose or microcrystalline cellulose, described adhesive is selected from：Cellulose derivative, pregelatinized starch, PVP,
The disintegrant is selected from：Sodium carboxymethyl starch, Ac-Di-Sol, PVPP, the lubricant are selected from：Talcum
Powder, magnesium stearate or superfine silica gel powder, it is preferred that the cellulose derivative is selected from：Methylcellulose, hydroxypropyl cellulose, carboxylic
Sodium carboxymethylcellulose pyce or ethyl cellulose.
9. purposes of the inonotus obliquus in antiprostate cancer is prepared.
10. purposes of the composition of inonotus obliquus and edible fungus polysaccharide in antiprostate cancer is prepared, it is preferred that institute
Edible fungus polysaccharide is stated to be selected from：One or more in lentinan, pachymaran, GL-B or flammulina velutipes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710298783.XA CN107028930B (en) | 2017-04-27 | 2017-04-27 | A kind of antiprostate cancer composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710298783.XA CN107028930B (en) | 2017-04-27 | 2017-04-27 | A kind of antiprostate cancer composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107028930A true CN107028930A (en) | 2017-08-11 |
| CN107028930B CN107028930B (en) | 2019-10-29 |
Family
ID=59537992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710298783.XA Expired - Fee Related CN107028930B (en) | 2017-04-27 | 2017-04-27 | A kind of antiprostate cancer composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107028930B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101391958A (en) * | 2008-11-10 | 2009-03-25 | 马宏达 | Extraction method of medicinal fungus inonotus obliquus component |
-
2017
- 2017-04-27 CN CN201710298783.XA patent/CN107028930B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101391958A (en) * | 2008-11-10 | 2009-03-25 | 马宏达 | Extraction method of medicinal fungus inonotus obliquus component |
Non-Patent Citations (3)
| Title |
|---|
| ZHONG XIU-HONG ET AL: "Progress of Research on Inonotus Obliquus", 《CHIN J INTEGR MED》 * |
| 刘立萍: "灵芝多糖的药理学作用（摘要）", 《第七次临床中药学术研讨会论文集》 * |
| 胡静娜: "噻唑蓝法测定香菇多糖体外对癌细胞毒作用", 《医药导报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107028930B (en) | 2019-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20170266213A1 (en) | Use of beta-nicotinamide mononucleotide in preparation of anti-aging drugs or health-care products | |
| WO2019174571A1 (en) | Pharmaceutical composition and use thereof in preparing drug for treating tumor multi-drug resistance | |
| KR20130131303A (en) | Anti-fatigue composition, formulation and use thereof | |
| CN103520151B (en) | γ-and the medical usage of Delta-Tocopherol and its derivative as radioprotectant | |
| CN102198150B (en) | Antitumor drug with double active components and application thereof | |
| CN107028930A (en) | A kind of antiprostate cancer composition and application thereof | |
| CN102872062A (en) | Medicinal composition for treating or preventing obesity and metabolic syndromes | |
| CN107260734A (en) | A kind of compound medicament composition with effect of anti-lung cancer and application thereof | |
| CN114939122B (en) | Combined antitumor pharmaceutical composition derived from natural plants | |
| CN102441000B (en) | Anti-cancer anti-disease buccal tablet | |
| CN104069194B (en) | A kind of Chinese medicine composition with antitumaous effect and its production and use | |
| CN105147696A (en) | Anti-breast cancer granules combining metformin hydrochloride and gdc 0941 and a preparation method thereof | |
| WO2009145411A2 (en) | Compositions for preventing or treating colon cancer comprising extracts from thorns of gleditsia sinensis | |
| CN111000862B (en) | Medicine composition for treating early cancer by targeting mitochondria and application thereof | |
| CN103919850B (en) | A kind of pharmaceutical composition and its application in antineoplastic is prepared | |
| KR20180101460A (en) | Uses of Sisotanke Tubulosa Extract and Isoquateroside in the Protection of Muscle | |
| CN101116665B (en) | Malaria-resisting arteannuin naphthoquine compound composition | |
| CN111298122A (en) | Pharmaceutical composition for treating small cell lung cancer and application thereof | |
| CN104367563A (en) | Tablet containing grifola frondosa and preparation method thereof | |
| CN105963293A (en) | Pharmaceutical composition for treating myocardial infarction and application thereof | |
| CN110693903B (en) | Medicine for treating acute monocytic leukemia and application of arsenic trioxide and dihydroartemisinin | |
| CN103142876A (en) | Preparation capable of improving functions of heart and cerebral vessels and use of oxygen and capable of delaying senescence | |
| CN102552284A (en) | Application of ergosterol in preparation of tumor multidrug resistance reversing medicines | |
| CN113893279B (en) | Application of Yiqing granules and cyclophosphamide combined medicine in antitumor treatment medicine | |
| CN109953999B (en) | Composition comprising Ganoderma polysaccharide and Polyporus polysaccharide with immunity enhancing effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191029 Termination date: 20200427 |